New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ACT;TEVA;ENDP;COV;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
April 1, 2015
08:11 EDTTEVATeva says receives FDA approval for ProAir RespiClick
Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration has approved ProAir RespiClick, albuterol sulfate, inhalation powder, a breath-actuated, multi-dose, dry-powder, short-acting beta-agonist inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. It is expected to become commercially available to patients during Q2.
07:43 EDTACTBofA/Merrill strategist holds an analyst/industry conference call
Subscribe for More Information
March 31, 2015
14:10 EDTTEVATeva deal yields cash, validation to Concert, says Ladenburg
Subscribe for More Information
10:01 EDTTEVAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:57 EDTACT, TEVAMomenta strength attributed to report of being viewed as takeover target
Subscribe for More Information
08:32 EDTTEVATeva launches generic Exforge tablets in the U.S.
Subscribe for More Information
08:21 EDTACTAmneal to acquire generic business of Actavis Australia
Subscribe for More Information
07:25 EDTTEVATeva upgraded at Oppenheimer
Subscribe for More Information
07:03 EDTTEVAAntares Pharma announces FDA approval of TEV-TROPIN
Antares Pharma announced that Ferring Pharmaceuticals has received FDA approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as Zomacton for injection, and the needle-free delivery system to be marketed in the U.S. as ZOMA-Jet. Ferring also received approval from the FDA to market the 10 mg needle-free injector device which, along with certain consumables, is supplied by Antares to Ferring. Ferring purchased the U.S. rights to Zomacton, formerly TEV-TROPIN, and to ZOMA-Jet, formerly Tjet, in December 2014 from Teva Pharmaceutical (TEVA). Ferring developed and has marketed Zomacton outside of the U.S. since 1988 and in 47 countries globally.
06:16 EDTTEVATeva upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
March 30, 2015
16:22 EDTTEVAOn The Fly: Closing Wrap
Subscribe for More Information
14:17 EDTTEVATeva Canada announces launch of Bortezomib for Injection
Subscribe for More Information
13:11 EDTTEVATeva made 'bold move' with Auspex deal, says BMO Capital
Subscribe for More Information
12:22 EDTTEVAOn The Fly: Midday Wrap
Subscribe for More Information
11:49 EDTTEVAAuspex downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
10:24 EDTABTMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
10:16 EDTTEVAAuspex Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:27 EDTABT, TEVAOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTABT, TEVATeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTTEVA, ABT, ACTMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
08:42 EDTTEVATeva says has capacity for additional acquisitions after Auspex deal
Teva (TEVA) says the Auspex (ASPX) transaction is not subject to shareholder approval. Comments from Teva CFO Eyal Desheh speaking on the Teva/Auspex conference call regarding the companies' transaction announced this morning.
07:03 EDTTEVATeva: Auspex deal represents total consideration of $3.2B in enterprise value
Subscribe for More Information
07:01 EDTTEVATeva to acquire Auspex Pharmaceuticals for $101 per share in cash
Subscribe for More Information
07:00 EDTTEVATeva to acquire Auspex Pharmaceuticals for $101 per share in cash
05:55 EDTTEVATeva may be close to large acquisition, Bloomberg reports
Analysts believe Teva may be close to making a large acquisition that could be announced by September, Bloomberg reports. Teva CEO Erez Vigodman said last month hat the company is shifting to an "inorganic growth" strategy, and CRT Capital analyst Timothy Chaing says that "The closer we get to September, the closer they’re going to get to to the finish line on completing a deal or at least announcing a deal." Reference Link
March 27, 2015
07:45 EDTTEVAFDA to hold a public meeting
Subscribe for More Information
07:25 EDTACT, TEVATeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
March 26, 2015
07:30 EDTTEVA, ACT, ENDPDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 25, 2015
12:58 EDTENDPPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
07:12 EDTENDPAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 24, 2015
07:45 EDTTEVAFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
06:22 EDTTEVATeva appointment shows transformative M&A not off table, says Citigroup
Subscribe for More Information
March 23, 2015
16:14 EDTACTPershing Square liquidates stake in Allergan
Subscribe for More Information
16:01 EDTTEVAOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
12:10 EDTTEVATeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
09:03 EDTABTFiserv says Abbott employee credit union expands partnership
Subscribe for More Information
08:50 EDTTEVATeva reports TEV-48125 met endpoints in phase 2b study
Subscribe for More Information
07:36 EDTACTPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
07:17 EDTACTAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
16:33 EDTENDPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
15:31 EDTENDPEndo management to meet with Sterne Agee
Subscribe for More Information
14:46 EDTACTNoven files patent infringement lawsuit against Actavis
Subscribe for More Information
07:41 EDTACTAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 18, 2015
16:13 EDTTEVAFibrocell Science appoints Keith Goldan as CFO
Fibrocell Science announced the appointment of Keith Goldan as senior VP and Chief Financial Officer, effective immediately. Prior to joining Fibrocell, Goldan served as CFO of two publicly traded companies. Most recently he served as SVP and CFO of NuPathe, which was acquired by Teva Pharmaceutical (TEVA) in 2014.
11:36 EDTTEVAIgnyta price target raised to $17 from $14 at Leerink
Subscribe for More Information
10:08 EDTTEVAEagle Pharmaceuticals price target increased to $67 from $43 at William Blair
William Blair raised its price target on Eagle Pharmaceuticals to $67 from $43 citing its belief that the company can become profitable and have significant cash flow pending the approval of EP-3102. The company added that it view last week's FDA label change for Teva's (TEVA) Treanda as a positive for EP-3102 and that its new price target assumes 2016 launch and "reasonable" penetration for EP-3102.
08:50 EDTACTActavis price target raised to $373 from $286 at BMO Capital
Subscribe for More Information
07:13 EDTTEVATeva volatility elevated, shares near four year high
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use